March 7, 2017
Mochida Pharmaceutical said on March 6 that it will codevelop Fuji Yakuhin’s investigational gout and hyperuricemia treatment FYU-981. FYU-981 stimulates the discharge of uric acid and has a different mechanism of action from that for the xanthine oxidase inhibitor Topiloric...read more